Amylon Therapeutics wins Startup Slam Competition at BIO-Europe® Berlin

Startup Slam sponsor Johnson & Johnson Innovation recognise high calibre of diverse European entries

09-Nov-2017 - Amylon Therapeutics was today announced as the winner of the Startup Slam competition at this year’s BIO-Europe® 2017 annual conference in Berlin. Thomas de Vlaam, CEO and founder of Amylon Therapeutics, will receive a complimentary registration to BIO-Europe® Spring 2018 from EBD Group and the ...

Heptares founder Richard Henderson receives Nobel Prize in Chemistry 2017

09-Oct-2017 - Heptares Therapeutics is delighted that one of its founders, Richard Henderson (MRC Laboratory of Molecular Biology, Cambridge, UK), was awarded the Nobel Prize in Chemistry 2017 together with Jacques Dubochet (University of Lausanne, Switzerland) and Joachim Frank (Columbia University, New York, ...

Heptares enters a research and drug discovery collaboration with Juntendo University

04-Sep-2017 - Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, announces the launch of a new research collaboration under its ORBIT initiative with Juntendo University in Tokyo, Japan. The new collaboration, Heptares’ fourth ORBIT programme, is with the research group of Professor ...

Enterome and Nestlé Health Science launch new diagnostics company

11-Jul-2017 - ENTEROME SA and Nestlé Health Science, announce the joint creation of Microbiome Diagnostics Partners (MDP). This company will bring together complementary, world-leading platforms and capabilities enabling the discovery and development of innovative diagnostics through to commercialization in ...

Heptares enters a Research and Drug Discovery Collaboration with New York University

New programme focused on key GPCR target implicated in aggressive brain cancer

28-Jun-2017 - Heptares Therapeutics announces the launch of a new research collaboration under its ORBIT initiative with New York University (NYU) School of Medicine. This new collaboration will support a multi-year programme with NYU’s drug discovery accelerator group, the Office of Therapeutics Alliances ...

Structure of CCR9 chemokine receptor solved

Offering opportunity to apply structure-based design across chemokine receptor family

08-Dec-2016 - Heptares Therapeutics announces that its scientists have solved the high-resolution X-ray crystal structure of the CCR9 receptor, a member of the chemokine receptor family. This family of G protein-coupled receptors (GPCRs) has diverse roles in immune defence by controlling the migration, ...

Cytos Biotechnology Ltd. is renamed Kuros Biosciences Ltd.

Kuros Biosurgery Holding Ltd. closes merger with Cytos Biotechnology Ltd.

21-Jan-2016 - Kuros Biosciences Ltd. announced the closing of the acquisition of Kuros Biosurgery Holding Ltd. and the change of name of the combined company to Kuros Biosciences Ltd. Starting 20 January 2016 all 508'432'244 Kuros Biosciences Ltd. shares are listed and freely tradable under the ticker symbol ...

Cytos Biotechnology and Kuros Biosurgery to combine

04-Dec-2015 - Cytos Biotechnology Ltd. and Kuros Biosurgery Holding AG, announced their intention to combine their businesses by way of an exchange of Kuros shares for new Cytos shares, subject to shareholder approval and other customary conditions. The combined entity will operate under the name "Kuros ...

Acquisition of PacificGMP by Abzena

Abzena has acquired PacificGMP

15-Sep-2015 - The acquisition of PacificGMP is in line with Abzena’s strategy to expand its offering and provides the opportunity to capture more value through broader support for its partners’ development projects and enables cross-selling of its services and technologies. The acquisition is expected to ...

Heptares and AstraZeneca enter agreement to develop treatments for a range of cancers

11-Aug-2015 - Heptares Therapeutics announced that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and ...